Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.32 |
| ▸ | IKBKB | O14920 | 2/20 | 0.32 |
| ▸ | CHUK | O15111 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL569064 | 0.80 | MEN1 (0.34) | MEN1KMT2AHSD17B10PTK2IKBKB | |
| SCHEMBL10274788 | 0.76 | MEN1 (0.32) | MEN1KMT2AHSD17B10PTK2IKBKB | |
| SCHEMBL569097 | 0.70 | CTSK (0.41) | KMT2APTK2IKBKBCHUK | |
| SCHEMBL23015749 | 0.68 | CHRNA7 (0.38) | IKBKBCHUK | |
| SCHEMBL1751661 | 0.66 | KMT2A (0.39) | MEN1KMT2AHSD17B10PTK2IKBKB | |
| SCHEMBL3128733 | 0.66 | PIK3C3 (0.35) | MEN1KMT2AHSD17B10PTK2IKBKB | |
| SCHEMBL27234420 | 0.66 | AR (0.42) | HSD17B10 | |
| SCHEMBL14479709 | 0.61 | MEN1 (0.45) | MEN1KMT2AHSD17B10PTK2IKBKB | |
| SCHEMBL17993855 | 0.59 | MEN1 (0.41) | MEN1KMT2AHSD17B10PTK2IKBKB | |
| SCHEMBL30311866 | 0.59 | IKBKB (0.35) | MEN1KMT2AHSD17B10IKBKBCHUK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163918-B2 | Azaindazole compounds as CCR1 receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-04-24 | — | — | US | disclosed |
| US-20120035370-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035370-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | CCR1, CCR3, CCR4 | MEN1 2598/4885KMT2A 2839/4885HSD17B10 3119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.